Literature DB >> 20600515

Two distinct chimeric potexviruses share antigenic cross-presentation properties of MHC class I epitopes.

Laïla-Aïcha Hanafi1, Marilène Bolduc, Marie-Eve Laliberté Gagné, Florent Dufour, Yves Langelier, Mohammed-Rachid Boulassel, Jean-Pierre Routy, Denis Leclerc, Réjean Lapointe.   

Abstract

Chimeric VLPs made of papaya mosaic virus (PapMV) trigger a CTL response through antigenic presentation of epitopes on MHC class I. Here, a chimeric VLP composed of malva mosaic virus (MaMV) was shown to share similar properties. We demonstrated the capacity of both VLPs to enter human APCs. The chimeric constructions were cross-presented in CD40-activated B lymphocytes leading to in vitro expansion of antigen-specific T lymphocytes. We showed that high concentrations of chimeric MaMV induced cell death, suggesting that some modifications can trigger collateral effects in vitro. Results suggest that potexvirus VLPs are an attractive vaccine platform for inducing a CTL response. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20600515     DOI: 10.1016/j.vaccine.2010.06.024

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  11 in total

Review 1.  Mechanisms of cellular and humoral immunity through the lens of VLP-based vaccines.

Authors:  Hunter McFall-Boegeman; Xuefei Huang
Journal:  Expert Rev Vaccines       Date:  2022-01-24       Impact factor: 5.217

Review 2.  Advancements in protein nanoparticle vaccine platforms to combat infectious disease.

Authors:  Nina Butkovich; Enya Li; Aaron Ramirez; Amanda M Burkhardt; Szu-Wen Wang
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2020-11-08

3.  Alfalfa mosaic virus nanoparticles-based in situ vaccination induces antitumor immune responses in breast cancer model.

Authors:  Mehdi Shahgolzari; Maghsoud Pazhouhandeh; Morteza Milani; Steven Fiering; Ahmad Yari Khosroushahi
Journal:  Nanomedicine (Lond)       Date:  2021-01-14       Impact factor: 5.307

Review 4.  Plant Viruses as Nanoparticle-Based Vaccines and Adjuvants.

Authors:  Marie-Ève Lebel; Karine Chartrand; Denis Leclerc; Alain Lamarre
Journal:  Vaccines (Basel)       Date:  2015-08-05

Review 5.  Repurposing Plant Virus Nanoparticles.

Authors:  Kathleen L Hefferon
Journal:  Vaccines (Basel)       Date:  2018-02-14

Review 6.  Plant Virus Expression Vectors: A Powerhouse for Global Health.

Authors:  Kathleen Hefferon
Journal:  Biomedicines       Date:  2017-07-30

7.  Engineering of papaya mosaic virus (PapMV) nanoparticles with a CTL epitope derived from influenza NP.

Authors:  Cindy Babin; Nathalie Majeau; Denis Leclerc
Journal:  J Nanobiotechnology       Date:  2013-04-04       Impact factor: 10.435

8.  A novel M2e based flu vaccine formulation for dogs.

Authors:  Denis Leclerc; Marie Rivest; Cindy Babin; Constantino López-Macias; Pierre Savard
Journal:  PLoS One       Date:  2013-10-02       Impact factor: 3.240

Review 9.  Reconceptualizing cancer immunotherapy based on plant production systems.

Authors:  Kathleen Hefferon
Journal:  Future Sci OA       Date:  2017-07-12

10.  A versatile papaya mosaic virus (PapMV) vaccine platform based on sortase-mediated antigen coupling.

Authors:  Ariane Thérien; Mikaël Bédard; Damien Carignan; Gervais Rioux; Louis Gauthier-Landry; Marie-Ève Laliberté-Gagné; Marilène Bolduc; Pierre Savard; Denis Leclerc
Journal:  J Nanobiotechnology       Date:  2017-07-18       Impact factor: 10.435

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.